Skye Bioscience, Inc.
skyebioscience.comWhat Do They Do?
Develops nimacimab, an antibody drug candidate targeting a metabolic receptor, for people with obesity and overweight.
10-K for FY2025, filed Mar 10, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$10.8MView ↗
- ▼ −39% (Loss)
- vs −$17.6M in Q2 FY2025
-
Sep 8, 2026
Chief financial officer resigned; CEO assumed the principal finance role
John P. Sharp resigned, and Punit Dhillon was appointed principal financial and accounting officer while remaining CEO.
Sources
8-K, filed Sep 11, 2026
On September 8, 2026, John P. Sharp resigned as Chief Financial Officer and principal financial and accounting officer of the Company…View ↗
-
Aug 14, 2026
Skye agreed to a proposed Redx Pharma acquisition
The transaction requires approval from both companies' shareholders; Skye also plans to pause nimacimab development.
Sources
8-K, filed Aug 14, 2026
On August 14, 2026, Skye Bioscience, Inc., a Nevada corporation (the “Company”), entered into a transaction agreement (“Transaction…View ↗
From eye treatments to metabolic disease
The older report centered on cannabinoid drug candidates for glaucoma and other eye conditions; the latest report centers on nimacimab, an antibody candidate for obesity, overweight, and related metabolic conditions.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 10, 2026
Who Do They Compete With?
Competes with Novo Nordisk, Eli Lilly, Structure Therapeutics, and Viking Therapeutics
10-K for FY2025, filed Mar 10, 2026The development and commercialization of therapies for the treatment of obesity and overweight is highly competitive. Our product…View ↗
Loading...
